ImmuPharma (LON:IMM) Stock Price Up 19.3% - What's Next?

Key Points

• ImmuPharma plc's stock price increased by 19.3% during mid-day trading, reaching GBX 12.94 ($0.18) with a trading volume that was 110% higher than its average daily volume.
• The company reported a net margin of 3,519.56% but has a negative return on equity of 131.41% and is projected to post an earnings per share of -339 for the fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 19.3% during mid-day trading on Friday . The stock traded as high as GBX 12.95 ($0.18) and last traded at GBX 12.94 ($0.18). Approximately 16,757,994 shares changed hands during mid-day trading, an increase of 110% from the average daily volume of 7,961,430 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Up 19.5%

The firm has a market cap of £64.81 million, a price-to-earnings ratio of -1,457.19 and a beta of 1.53. The stock's 50 day moving average is GBX 2.88 and its 200 day moving average is GBX 2.86.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.